Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 25,500 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, May 14th. The stock was purchased at an average price of $8.20 per share, with a total value of $209,100.00. Following the completion of the purchase, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $16,297,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

OPK has been the subject of a number of recent research reports. Analysts at TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday. Separately, analysts at Oppenheimer cut their price target on shares of Opko Health from $13.00 to $12.00 in a research note on Monday. They now have an “outperform” rating on the stock. Finally, analysts at Ned Davis Research upgraded shares of Opko Health from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $12.50.

Opko Health (NYSE:OPK) traded down 0.98% during mid-day trading on Thursday, hitting $8.10. 879,595 shares of the company’s stock traded hands. Opko Health has a 1-year low of $6.14 and a 1-year high of $12.95. The stock has a 50-day moving average of $8.63 and a 200-day moving average of $9.09. The company’s market cap is $3.284 billion. Opko Health also saw a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 50,337,366 shares, an increase of 6.2% from the April 15th total of 47,379,151 shares. Currently, 23.4% of the company’s shares are short sold. Based on an average daily volume of 2,431,204 shares, the short-interest ratio is presently 20.7 days.

Opko Health (NYSE:OPK) last released its earnings data on Friday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. Analysts expect that Opko Health will post $-0.36 EPS for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.